Posted by Michael Wonder on 10 Sep 2025
Enhanced access to generalised myasthenia gravis treatments: UCB Canada secures pCPA agreements for Zilbrysq and Rystiggo
9 September 2025 - Important milestone brings eligible Canadians living with generalised myasthenia gravis one step closer to accessing innovative therapies Zilbrysq and Rystiggo through public reimbursement, marking progress towards increased patient access to two different mechanisms of action.
UCB Canada is proud to announce that the pan-Canadian Pharmaceutical Alliance has successfully concluded negotiations for Zilbrysq (zilucoplan injection) and Rystiggo (rozanolixizumab injection), marking an important milestone in creating access for these innovative therapies for Canadians living with generalised myasthenia gravis.
